Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 30;7(1):105-10.
doi: 10.1021/acsmedchemlett.5b00429. eCollection 2016 Jan 14.

Potent Small Agonists of Protease Activated Receptor 2

Mei-Kwan Yau  1 , Jacky Y Suen  1 , Weijun Xu  1 , Junxian Lim  1 , Ligong Liu  1 , Mark N Adams  2 , Yaowu He  2 , John D Hooper  2 , Robert C Reid  1 , David P Fairlie  1
Affiliations

Potent Small Agonists of Protease Activated Receptor 2

Mei-Kwan Yau et al. ACS Med Chem Lett. .

Abstract

Many proteases cut the PAR2 N-terminus resulting in conformational changes that activate cells. Synthetic peptides corresponding to newly exposed N-terminal sequences of PAR2 also activate the receptor at micromolar concentrations. PAR2-selective small molecules reported here induce PAR2-mediated intracellular calcium signaling at nanomolar concentrations (EC50 = 15-100 nM, iCa(2+), CHO-hPAR2 cells). These are the most potent and efficient small molecule ligands to activate PAR2-mediated calcium release and chemotaxis, including for human breast and prostate cancer cells.

Keywords: Protease activated receptor 2; agonist; cyclohexylglycine; structure−activity relationships.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing financial interest(s): D.P.F., L.L., M.K.Y., J.Y.S., and R.R. are named inventors on US Patent 8,927,503 and are co-authors on this manuscript. The patent is owned by the University of Queensland and concerns agonists and antagonists of PAR2.

Figures

Figure 1
Figure 1
Known synthetic PAR2 agonists.,,−
Figure 2
Figure 2
Predicted binding mode for agonist 14 in a PAR2 homology model derived from nociceptin/orphanin FQ receptor (pdb code 4EA3). (A) Agonist AY77 (14) is predicted to form multiple hydrogen bonds and hydrophobic interactions with PAR2. (B) Surface view of PAR2 model showing Isox, Cha, and Chg components occupying three distinct binding pockets. (C) iCa2+ responses induced by agonist 14 were significantly reduced in PAR2 mutants Y156A, Y326A, D228A, L307A, and Y82A compared to wild-type (WT), suggesting that these residues interact with 14. Each data point is mean ± SEM of 3–5 independent experiments. (D) The C-terminal amide NH2 of 14 forms hydrogen bonds with Y156 and D228. The cyclohexylglycine may make a hydrophobic interaction with L307 and the amide carbonyl of Cha may form a water mediated H-bond with Y326. Isoxazole may form a H-bond with Y82.
Figure 3
Figure 3
(a) Agonist 14 was stable in rat plasma after 4 h (pH 7.4, 37 °C, initial concentration 1 μM) compared to peptides 1 and 6. The plasma samples were analyzed by LCMS (n = 3). (b) Agonists 1 and 14 (AY77) activate Ca2+ release via PAR2. Experiments were performed in CHO-hPAR2 cells (solid lines) versus CHO cells (PAR2–/–, dotted lines), n ≥ 3. Each data point represents mean ± SEM.
Figure 4
Figure 4
PAR2-activated chemotaxis in MDA-MB-231 breast cancer cells. Compounds 1 and 14 (100 nM) induced chemotaxis in a transwell migration assay. Preincubating cells with PAR2 antibody SAM11 (1 μg/mL) 30 min prior to agonist addition resulted in inhibition of chemotaxis. The chemotactic index is the ratio of agonist to random migration (24 h) through a 5 μm membrane, mean ± SEM, ***p < 0.001.
See this image and copyright information in PMC

References

    1. Adams M. N.; Ramachandran R.; Yau M. K.; Suen J. Y.; Fairlie D. P.; Hollenberg M. D.; Hooper J. D. Structure, function and pathophysiology of protease activated receptors. Pharmacol. Ther. 2011, 130, 248–282. 10.1016/j.pharmthera.2011.01.003. - DOI - PubMed
    1. Rothmeier A. S.; Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin. Immunopathol. 2012, 34, 133–149. 10.1007/s00281-011-0289-1. - DOI - PubMed
    1. Yau M. K.; Liu L.; Fairlie D. P. Toward drugs for protease-activated receptor 2 (PAR2). J. Med. Chem. 2013, 56, 7477–7497. 10.1021/jm400638v. - DOI - PubMed
    1. Elmariah S. B.; Reddy V. B.; Lerner E. A.; Cathepsin S. Signals via PAR2 and Generates a Novel Tethered Ligand Receptor Agonist. PLoS One 2014, 9, e99702. 10.1371/journal.pone.0099702. - DOI - PMC - PubMed
    1. Zhao P.; Lieu T.; Barlow N.; Metcalf M.; Veldhuis N. A.; Jensen D. D.; Kocan M.; Sostegni S.; Haerteis S.; Baraznenok V.; Henderson I.; Lindstrom E.; Guerrero-Alba R.; Valdez-Morales E. E.; Liedtke W.; McIntyre P.; Vanner S. J.; Korbmacher C.; Bunnett N. W. Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4. J. Biol. Chem. 2014, 289, 27215–27234. 10.1074/jbc.M114.599712. - DOI - PMC - PubMed

LinkOut - more resources